Haemonetics (HAE) Competitors $75.55 -2.62 (-3.35%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$74.70 -0.85 (-1.13%) As of 07/11/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, COO, and ALGNShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Cooper Companies (COO), and Align Technology (ALGN). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Cooper Companies Align Technology Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is HAE or DXCM more profitable? DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets Haemonetics12.32% 26.37% 9.22% DexCom 12.90%30.05%10.00% Which has higher valuation & earnings, HAE or DXCM? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHaemonetics$1.36B2.67$167.68M$3.3122.82DexCom$4.03B8.11$576.20M$1.3462.22 Do insiders and institutionals believe in HAE or DXCM? 99.7% of Haemonetics shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, HAE or DXCM? Haemonetics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Does the media prefer HAE or DXCM? In the previous week, DexCom had 2 more articles in the media than Haemonetics. MarketBeat recorded 19 mentions for DexCom and 17 mentions for Haemonetics. DexCom's average media sentiment score of 1.43 beat Haemonetics' score of 0.80 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 15 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer HAE or DXCM? Haemonetics currently has a consensus price target of $97.30, indicating a potential upside of 28.79%. DexCom has a consensus price target of $98.50, indicating a potential upside of 18.15%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Haemonetics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95 SummaryDexCom beats Haemonetics on 12 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.63B$10.56B$5.55B$20.65BDividend YieldN/A2.09%5.07%3.72%P/E Ratio22.8216.8328.2127.82Price / Sales2.6730.17431.9542.48Price / Cash10.4822.5637.1222.32Price / Book4.623.668.044.57Net Income$167.68M$235.43M$3.19B$989.30M7 Day Performance-1.69%1.27%3.63%0.20%1 Month Performance5.98%2.95%4.06%3.95%1 Year Performance-16.57%-15.74%30.02%10.27% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.9095 of 5 stars$75.55-3.4%$97.30+28.8%-15.6%$3.63B$1.36B22.823,023News CoverageAnalyst UpgradeAnalyst RevisionDXCMDexCom4.821 of 5 stars$82.94+0.0%$98.50+18.8%-26.0%$32.52B$4.03B61.9010,300Positive NewsHQYHealthEquity3.8771 of 5 stars$101.83-0.3%$118.09+16.0%+24.8%$8.83B$1.20B74.333,120Positive NewsAnalyst ForecastInsider TradeLNTHLantheus4.5873 of 5 stars$79.19-1.5%$130.50+64.8%-34.2%$5.56B$1.53B22.50700News CoveragePositive NewsPODDInsulet4.5394 of 5 stars$300.70-0.1%$321.00+6.8%+42.1%$21.19B$2.07B54.083,900Positive NewsAnalyst ForecastQTRXQuanterix2.4438 of 5 stars$6.30-9.7%$15.60+147.6%-58.2%$348.68M$137.42M-4.85460News CoveragePositive NewsSIBNSiBone4.0012 of 5 stars$18.01-2.5%$22.50+24.9%+16.8%$787.09M$167.18M-28.14350PENPenumbra4.8173 of 5 stars$248.05-1.2%$302.40+21.9%+27.4%$9.72B$1.19B234.014,500News CoverageAnalyst ForecastInsider TradeZBHZimmer Biomet4.9506 of 5 stars$92.58-1.2%$111.33+20.3%-13.2%$18.53B$7.68B20.4817,000Analyst ForecastCOOCooper Companies3.1463 of 5 stars$73.290.0%$99.70+36.0%-15.6%$14.66B$3.90B35.5816,000Positive NewsAnalyst DowngradeHigh Trading VolumeALGNAlign Technology4.6263 of 5 stars$193.83-1.5%$241.25+24.5%-21.1%$14.27B$4.00B35.3120,945Positive NewsAnalyst Forecast Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Cooper Companies Alternatives Align Technology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
